Internal Medicine Doctors in Chamblee, GA Accepting Medicare
3 Internal Medicine doctors found. Showing 1 - 3
 Dr. Joy Hsu, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 4770 Buford Hwy, Ms F-60, Chamblee, GA 30341 Phone: 770-488-0788 |
Dr. Sue A Brenner, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3807 Clairmont Rd, Chamblee, GA 30341 Phone: 404-616-0700 |
 Dr. Nipun Patel, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3646 Chamblee Tucker Rd Ste B, Chamblee, GA 30341 Phone: 770-493-6767 Fax: 770-493-6797 |
News Archive
Traffic light colors have favorable effect on healthy food choices of consumers
Which products end up in your shopping basket? If the packaging information also features food traffic light colors, fewer products are chosen purely based on taste and more based on health aspects compared with nutritional information purely in percentages and grams.
Novant to use MEDai's Pinpoint Review patient-specific early-warning system
MEDai, Inc., an Elsevier company and leading provider of advanced solutions for healthcare that utilize award-winning predictive analytics, announced today that Novant Health, a not-for-profit integrated group of hospitals and physician practices, will roll out MEDai's Pinpoint Review(TM) to its nine hospitals in North Carolina, Virginia and South Carolina.
20th annual edition of NCCN Guidelines for Prostate Cancer published
The National Comprehensive Cancer Network has published the 20th annual edition of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer—one of the eight original NCCN Guidelines published in November 1996.
IMD seeks FDA regulatory clearance for NADiA ProsVue prostate cancer prognostic test
IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that its IRIS Molecular Diagnostics (IMD) subsidiary has submitted a 510(k) pre-market notification application to the U.S. Food and Drug Administration (FDA) requesting regulatory clearance for NADiA®ProsVue™, a prostate cancer prognostic test. The test is designed to help physicians identify patients at low risk of cancer recurrence post radical prostatectomy.
Beta blockers may improve effectiveness of triple negative breast cancer treatments
New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor.
› Verified 2 days ago
Pediatrics
Family Medicine
Internal Medicine
General Practice
Surgery
Psychiatry & Neurology
Pathology
Ophthalmology